Choe Eun Kyung, Park Kyu Joo, Chung Su Jin, Moon Sang Hui, Ryoo Seung-Bum, Oh Heung-Kwon
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Digestion. 2015;91(2):142-9. doi: 10.1159/000370308. Epub 2015 Feb 10.
BACKGROUND/AIMS: Although there are guidelines for colonoscopic surveillance after colorectal cancer (CRC) surgery, the data evaluating the effectiveness of these guidelines are limited. We determined the risk factors for metachronous neoplasia (MN) by performing annual colonoscopy examinations after curative resection.
We performed annual colonoscopic surveillance on stage I-III CRC patients after curative resection. We stratified the patients based on the advanced neoplasia risk during the surveillance.
Advanced MN detected was in 59 (13.1%) of 451 patients. Overall, the cumulative incidence of advanced MN was 17.3% at 5 years. By the multivariate analysis, the risk factors for advanced MN were male gender, age >65, left-sided index cancer and being in the high-risk group. The cumulative incidence of advanced MN was 38.9% at 5 years in the high-risk group. Among the patients who had advanced MN, secondary advanced MN was detected in 13 patients (22.0%) with a subsequent colonoscopy. The 2-year cumulative incidence of secondary advanced MN was 16.9%. Four (0.88%) patients had metachronous CRC during the surveillance and the interval from the index CRC was a median of 58.5 months.
Although the current follow-up guidelines for colonoscopic surveillance after CRC are well established, the high-risk group calls for more meticulous follow-up, which should be continued for a sufficient time.
背景/目的:尽管有关于结直肠癌(CRC)手术后结肠镜监测的指南,但评估这些指南有效性的数据有限。我们通过在根治性切除术后进行年度结肠镜检查来确定异时性肿瘤(MN)的危险因素。
我们对根治性切除术后的I-III期CRC患者进行年度结肠镜监测。我们根据监测期间高级别肿瘤的风险对患者进行分层。
451例患者中有59例(13.1%)检测到高级别MN。总体而言,5年时高级别MN的累积发病率为17.3%。通过多变量分析,高级别MN的危险因素为男性、年龄>65岁、左半结肠癌以及属于高危组。高危组5年时高级别MN的累积发病率为38.9%。在患有高级别MN的患者中,13例(22.0%)在随后的结肠镜检查中检测到继发性高级别MN。继发性高级别MN的2年累积发病率为16.9%。4例(0.88%)患者在监测期间发生异时性CRC,距原发CRC的间隔时间中位数为58.5个月。
尽管目前CRC术后结肠镜监测的随访指南已确立,但高危组需要更细致的随访,且应持续足够长的时间。